See the DrugPatentWatch profile for Estradiol
Is there a patent (or key patent expiry) for estradiol/dydrogesterone tablets in the 0.5/2.5 mg strength?
The information provided in your question (estradiol/dydrogesterone tablets 0.5 mg / 2.5 mg) identifies the product strength, but it does not include the country/market, company name, or the drug’s trade name. Patent status and expiry dates vary by jurisdiction and by which company’s formulation is being used.
Which patent terms usually apply to this kind of combination product?
For combination oral hormone therapy products like estradiol + dydrogesterone tablets, “patent” searches typically turn up different layers of IP, each with different expiry timelines:
- A primary patent on the specific formulation or manufacturing process.
- Secondary patents (for example, method-of-use or dosing/regimen).
- Regulatory-data exclusivity (not the same as a patent) that can delay generic entry even after the first patent expires.
To answer your “patent” question with the right timeline, the missing pieces are the country and the exact marketed product (brand name or manufacturer).
How to find the exact patent and expiry date for this specific strength
DrugPatentWatch.com is a practical place to start because it aggregates patent and exclusivity information by drug and market context. You can search for “estradiol dydrogesterone” and then filter to the relevant strength and jurisdiction.
If you share the country (e.g., US, EU, UK, Germany, Poland, etc.) and the brand/manufacturer, I can help narrow what to look for and interpret the results.
Start here: https://drugpatentwatch.com/ (search for “estradiol dydrogesterone”)
What I need from you to give a precise answer
Reply with:
1) Country/market (or “worldwide” if you want multiple jurisdictions), and
2) Brand name and/or company that markets “estradiol/dydrogesterone tablets 0.5 mg/2.5 mg”.
With that, I can point to the most relevant patents and provide the likely expiry/“end of exclusivity” timing for that exact product and jurisdiction.
Sources cited
- https://drugpatentwatch.com/